Scandinavian ChemoTech AB (publ) (FRA:8V6)

Scandinavian ChemoTech AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	12.29	6.57	2.82	0.47	2.59
Revenue	12.29	6.57	2.82	0.47	2.59
Revenue Growth (YoY)	87.10%	132.67%	496.62%	-81.70%	82.82%
Cost of Revenue	1.99	1.79	1.16	0.53	-0.27
Gross Profit	10.3	4.78	1.66	-0.06	2.86
Selling, General & Admin	14.63	15.41	19.12	17.86	16.96
Other Operating Expenses	0.16	0.11	0.1	0.05	0.16
Operating Expenses	16.76	17.57	21.9	20.86	19.94
Operating Income	-6.46	-12.8	-20.24	-20.91	-17.08
Interest Expense	-1.59	-1.18	-1.4	-1.9	-0.68
Interest & Investment Income	-	0.26	0.55	0.06	0.01
Pretax Income	-8.06	-13.72	-21.09	-22.75	-17.74
Net Income	-8.06	-13.72	-21.09	-22.75	-17.74
Net Income to Common	-8.06	-13.72	-21.09	-22.75	-17.74
Shares Outstanding (Basic)	24	21	13	10	9
Shares Outstanding (Diluted)	24	21	13	10	9
Shares Change (YoY)	16.32%	53.13%	35.31%	15.17%	75.79%
EPS (Basic)	-0.34	-0.66	-1.56	-2.28	-2.05
EPS (Diluted)	-0.34	-0.66	-1.56	-2.28	-2.05
Free Cash Flow	-3.74	-18.23	-18.23	-19.49	-19.24
Free Cash Flow Per Share	-0.16	-0.88	-1.35	-1.96	-2.22
Gross Margin	83.81%	72.75%	58.75%	-11.63%	110.60%
Operating Margin	-52.61%	-194.88%	-717.12%	-4421.14%	-660.62%
Profit Margin	-65.58%	-208.91%	-747.38%	-4808.88%	-686.38%
Free Cash Flow Margin	-30.48%	-277.58%	-645.85%	-4119.87%	-744.18%
EBITDA	-4.49	-12.63	-20.13	-20.87	-17.04
EBITDA Margin	-36.55%	-192.40%	-	-	-
D&A For EBITDA	1.97	0.16	0.11	0.04	0.04
EBIT	-6.46	-12.8	-20.24	-20.91	-17.08
EBIT Margin	-52.61%	-194.88%	-	-	-
Revenue as Reported	12.39	6.77	2.98	0.51	2.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.